By Ellen Gilbert
Recent strides in the field of genetic engineering are generating tremendous excitement. Long in the works at university and company laboratories, the implications of this treatment are far-reaching.
The rapidly emerging immunotherapy approach is called adoptive cell transfer (ACT); it collects and uses patients’ own immune cells to treat their cancer. There are several types of ACT, but the star of the show right now is CAR T-cell therapy, which made medical history this last August when the Food and Drug Administration (FDA) approved the first genetic therapy for widespread use. Called Kymriah, it is being marketed by Novartis, a global healthcare company based in Switzerland. more